Pre-made Ponsegromab benchmark antibody ( Whole mAb, anti-GDF15 therapeutic antibody, Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ponsegromab biosimilar, Whole mAb, Anti-GDF15 Antibody: Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ponsegromab (formerly PF 06946860) is a subcutaneously administered, growth factor inhibitor, being developed by Pfizer, for the treatment of cachexia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-451-1mg	1mg	3090
GMP-Bios-ab-451-10mg	10mg	Inquiry
GMP-Bios-ab-451-100mg	100mg	Inquiry
GMP-Bios-ab-451-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ponsegromab biosimilar, Whole mAb, Anti-GDF15 Antibody: Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB therapeutic antibody
INN Name	Ponsegromab
Target	GDF15
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Pfizer
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	na
Development Tech	na